EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Opaganib Protects Against High-Fat Diet-Induced Hypercholesterolemia and Liver Steatosis in Mice

Lynn W Maines, Staci N Keller, Ryan A Smith, Charles D Smith iD

Diabetes, Metabolic Syndrome and Obesity · 2026-10 · Volume 19 · 1-18

DOI: 10.2147/dmso.s617948 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Metabolic Syndrome and Obesity, 2026-10. Verfasst von Lynn W Maines und 3 weiteren Autor:innen. Beteiligte Einrichtung: Apogee Biotechnology Corporation, Hummelstown, PA, USA. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

ABC294640fatty liverhypercholesterolemiametabolic dysfunction-associated steatotic liver diseaseobesityopaganibsphingolipids

Autor:innen und Institutionen

  • Apogee Biotechnology Corporation, Hummelstown, PA, USA.

ORCID-Profile: Charles D Smith

Zitieren

APA

Maines, L. W., Keller, S. N., Smith, R. A., & Smith, C. D. (2026). Opaganib Protects Against High-Fat Diet-Induced Hypercholesterolemia and Liver Steatosis in Mice. Diabetes, Metabolic Syndrome and Obesity, Volume 19, 1-18. https://doi.org/10.2147/dmso.s617948

Vancouver

Maines LW, Keller SN, Smith RA, Smith CD. Opaganib Protects Against High-Fat Diet-Induced Hypercholesterolemia and Liver Steatosis in Mice. Diabetes, Metabolic Syndrome and Obesity. 2026;Volume 19:1-18. doi:10.2147/dmso.s617948

BibTeX
@article{Maines2026,
  author = {Maines, Lynn W and Keller, Staci N and Smith, Ryan A and Smith, Charles D},
  title = {Opaganib Protects Against High-Fat Diet-Induced Hypercholesterolemia and Liver Steatosis in Mice},
  journal = {Diabetes, Metabolic Syndrome and Obesity},
  year = {2026},
  volume = {Volume 19},
  pages = {1--18},
  doi = {10.2147/dmso.s617948}
}
Kostenlos starten →